Literature DB >> 21475810

Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.

Yutaro Suzuki1, Hideki Murakami, Koji Kawaguchi, Tetsuo Tanigushi, Makiko Fujii, Keiko Shinjo, Yutaka Kondo, Hirotaka Osada, Kaoru Shimokata, Yoshitsugu Horio, Yoshinori Hasegawa, Toyoaki Hida, Yoshitaka Sekido.   

Abstract

Malignant mesothelioma (MM) is a highly aggressive neoplasm, which is associated with asbestos exposure. The dysregulated phosphatidylinositol 3-kinase (PI3K)-AKT pathway plays an important role in cell proliferation, survival and motility in various cancers. In this study, we analyzed the activation status and underlying mechanisms of this pathway in MM cells using 21 cell lines. AKT activation was observed in 13 (62%) of the 21 MM cell lines under serum-starved conditions. Two cell lines, ACC-MESO-1 and Y-MESO-25, showed no expression of PTEN protein, while 7 other cell lines showed low expression of PTEN mRNA and protein compared to expression levels in an immortalized normal mesothelial cell line, MeT-5A. We found that PTEN inactivation in the ACC-MESO-1 and Y-MESO-25 lines was due to a 39.4-kb deletion including PTEN exon 2, and to a 7.7-kb deletion including exon 1, respectively. Re-expression of PTEN in these cells reduced the activity of colony formation in vitro. In contrast, no mutation of PIK3CA or LKB1 was found in any of the MM cell lines. These findings suggest that AKT is frequently activated in MM cells, in part due to the downregulation of PTEN. Thus, the PI3K-AKT signaling pathway is a potential therapeutic target for MM.

Entities:  

Year:  2009        PMID: 21475810     DOI: 10.3892/mmr_00000081

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  16 in total

Review 1.  Pathological and molecular biological approaches to early mesothelioma.

Authors:  Tohru Tsujimura; Ikuko Torii; Ayuko Sato; Misa Song; Kazuya Fukuoka; Seiki Hasegawa; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2012-01-12       Impact factor: 3.402

2.  SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Authors:  Sai-Hong Ignatius Ou; James Moon; Linda L Garland; Philip C Mack; Joseph R Testa; Anne S Tsao; Antoniette J Wozniak; David R Gandara
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

3.  PTEN protein expression in malignant pleural mesothelioma.

Authors:  Vijay Agarwal; Anne Campbell; Kate L Beaumont; Lynn Cawkwell; Michael J Lind
Journal:  Tumour Biol       Date:  2012-12-15

Review 4.  The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms.

Authors:  Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Tumour Biol       Date:  2013-10-01

Review 5.  DNA repair and damage pathways in mesothelioma development and therapy.

Authors:  Faezeh Malakoti; Niloufar Targhazeh; Erfan Abadifard; Reza Zarezadeh; Sahar Samemaleki; Zatollah Asemi; Simin Younesi; Reza Mohammadnejad; Seyed Hadi Hossini; Ansar Karimian; Forough Alemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-05-02       Impact factor: 6.429

6.  Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.

Authors:  Y Guo; L R Chirieac; R Bueno; H Pass; W Wu; I A Malinowska; D J Kwiatkowski
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

7.  Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.

Authors:  R Mezzapelle; U Miglio; O Rena; A Paganotti; S Allegrini; J Antona; F Molinari; M Frattini; G Monga; O Alabiso; R Boldorini
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

8.  EphB4 as a therapeutic target in mesothelioma.

Authors:  Ren Liu; Benjamin D Ferguson; Yue Zhou; Kranthi Naga; Ravi Salgia; Parkash S Gill; Valery Krasnoperov
Journal:  BMC Cancer       Date:  2013-05-30       Impact factor: 4.430

9.  Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models.

Authors:  Dario Barbone; Carlo Follo; Nohemy Echeverry; Victor H Gerbaudo; Astero Klabatsa; Raphael Bueno; Emanuela Felley-Bosco; V Courtney Broaddus
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

10.  Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation.

Authors:  Yoon-Jin Lee; Jae-Hyuk Im; David M Lee; Ji-Sung Park; Seong Youn Won; Moon-Kyun Cho; Hae-Seon Nam; Yong-Jin Lee; Sang-Han Lee
Journal:  BMB Rep       Date:  2012-11       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.